Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Udo Holtick

Showing results (51-60 of 95) with videos related to

Pageof 10
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|January 31, 2022
Salvage High-dose Melphalan With Autologous Stem cell Transplantation as Bridge to Consolidation Therapy for Chemoresistant Aggressive B-cell LymphomaDominic Kaddu-Mulindwa, Philipp Gödel, Nadine Kutsch, et al.
Transplantation and Cellular Therapy|November 7, 2022
Mocravimod, a Selective Sphingosine-1-Phosphate Receptor Modulator, in Allogeneic Hematopoietic Stem Cell Transplantation for MalignancySimone Dertschnig, Peter Gergely, Jürgen Finke, et al.
European Journal of Haematology|February 24, 2015
OCTET-CY: a phase II study to investigate the efficacy of post-transplant cyclophosphamide as sole graft-versus-host prophylaxis after allogeneic peripheral blood stem cell transplantationUdo Holtick, Jens-Markus Chemnitz, Alexander Shimabukuro-Vornhagen, et al.
Ejhaem|September 2, 2025
Early Free Light-Chain Suppression as a Prognostic Marker in Relapsed and Refractory Myeloma Patients Treated With BCMA-Directed CAR-T CellsTim Richardson, Hishan Tharmaseelan, Guido Kobbe, et al.
Annals of Hematology|November 17, 2022
Characteristics and outcomes of patients undergoing high-dose chemotherapy and autologous stem cell transplantation admitted to the intensive care unit: a single-center retrospective analysisJorge Garcia Borrega, Boris Böll, Matthias Kochanek, et al.
Blood Advances|July 11, 2025
Sequential BCMA CAR-T Cell Therapy in Refractory Multiple MyelomaTim Richardson, Udo Holtick, Jan Hendrik Frenking, et al.
Blood Advances|June 13, 2022
Hematopoietic stem cell boost for persistent neutropenia after CAR T-cell therapy: a GLA/DRST studyNico Gagelmann, Gerald Georg Wulf, Johannes Duell, et al.
Human Gene Therapy|August 30, 2017
Automated Manufacturing of Potent CD20-Directed Chimeric Antigen Receptor T Cells for Clinical UseDominik Lock, Nadine Mockel-Tenbrinck, Katharina Drechsel, et al.
Microorganisms|August 27, 2021
Combined Therapy with Intravenous Immunoglobulins, Letermovir and (Val-)Ganciclovir in Complicated Courses of CMV-Infection in Transplant RecipientsVeronica Di Cristanziano, Patrick Affeldt, Moritz Trappe, et al.
Frontiers in Oncology|October 8, 2024
How to optimize the CAR-T Cell therapy process? A group concept mapping analysis of preconditions for a frictionless process from a German multistakeholder perspectiveAnn-Cathrine Siefen, Melina Sophie Kurte, Florian Jakobs, et al.
Pageof 10

Showing results (51-60 of 95) with videos related to

Sort By:
Pageof 10
Clinical Lymphoma, Myeloma & Leukemia|January 31, 2022
Salvage High-dose Melphalan With Autologous Stem cell Transplantation as Bridge to Consolidation Therapy for Chemoresistant Aggressive B-cell LymphomaDominic Kaddu-Mulindwa, Philipp Gödel, Nadine Kutsch, et al.
Transplantation and Cellular Therapy|November 7, 2022
Mocravimod, a Selective Sphingosine-1-Phosphate Receptor Modulator, in Allogeneic Hematopoietic Stem Cell Transplantation for MalignancySimone Dertschnig, Peter Gergely, Jürgen Finke, et al.
European Journal of Haematology|February 24, 2015
OCTET-CY: a phase II study to investigate the efficacy of post-transplant cyclophosphamide as sole graft-versus-host prophylaxis after allogeneic peripheral blood stem cell transplantationUdo Holtick, Jens-Markus Chemnitz, Alexander Shimabukuro-Vornhagen, et al.
Ejhaem|September 2, 2025
Early Free Light-Chain Suppression as a Prognostic Marker in Relapsed and Refractory Myeloma Patients Treated With BCMA-Directed CAR-T CellsTim Richardson, Hishan Tharmaseelan, Guido Kobbe, et al.
Annals of Hematology|November 17, 2022
Characteristics and outcomes of patients undergoing high-dose chemotherapy and autologous stem cell transplantation admitted to the intensive care unit: a single-center retrospective analysisJorge Garcia Borrega, Boris Böll, Matthias Kochanek, et al.
Blood Advances|July 11, 2025
Sequential BCMA CAR-T Cell Therapy in Refractory Multiple MyelomaTim Richardson, Udo Holtick, Jan Hendrik Frenking, et al.
Blood Advances|June 13, 2022
Hematopoietic stem cell boost for persistent neutropenia after CAR T-cell therapy: a GLA/DRST studyNico Gagelmann, Gerald Georg Wulf, Johannes Duell, et al.
Human Gene Therapy|August 30, 2017
Automated Manufacturing of Potent CD20-Directed Chimeric Antigen Receptor T Cells for Clinical UseDominik Lock, Nadine Mockel-Tenbrinck, Katharina Drechsel, et al.
Microorganisms|August 27, 2021
Combined Therapy with Intravenous Immunoglobulins, Letermovir and (Val-)Ganciclovir in Complicated Courses of CMV-Infection in Transplant RecipientsVeronica Di Cristanziano, Patrick Affeldt, Moritz Trappe, et al.
Frontiers in Oncology|October 8, 2024
How to optimize the CAR-T Cell therapy process? A group concept mapping analysis of preconditions for a frictionless process from a German multistakeholder perspectiveAnn-Cathrine Siefen, Melina Sophie Kurte, Florian Jakobs, et al.
Pageof 10